Dr. John Leonard

Nearly 200 scientists, investors and industry representatives attended Weill Cornell Medicine’s 2025 Biomedical Innovation Conference April 1, sharing their startup journeys and experiences nurturing biomedical advances into health care products and companies.

In its eighth year, the annual Dean's Symposium on Innovation and Entrepreneurship celebrates innovation and Weill Cornell Medicine’s entrepreneurial spirit, while encouraging and motivating the next generation of innovators, inventors and entrepreneurs.

Weill Cornell Medicine has received a five-year, $12.4 million grant from the National Cancer Institute, part of the National Institutes of Health, for an extensive program of basic and translational research on the biology of diffuse large B-cell lymphoma (DLBCL), the most common form of lymphoma.

The 2024 Business Plan Challenge accelerator program culminated in a pitch competition with five finalist teams putting their knowledge and marketing skills to the test. 

The 2024 Startup Symposium & InvestConnect Conference celebrated scientific inquiry and the entrepreneurial spirit.

Awards, honors and achievements for the month of November.  

The Dean’s Symposium  on Innovation and Entrepreneurship, which took place Nov. 7, celebrated innovation and Weill Cornell Medicine’s entrepreneurial spirit.

Dr. Maya Hogg, a leading hospitalist, has been appointed chief of medicine at NewYork-Presbyterian Lower Manhattan Hospital and vice chair in the Weill Department of Medicine at Weill Cornell Medicine.

Dr. Jonathan Weinsaft, an esteemed physician-scientist who focuses on clinical research and cardiovascular imaging, has been appointed chief of the Greenberg Division of Cardiology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, effective July 1.

Nearly 90 percent of patients with an aggressive subtype of non-Hodgkin lymphoma had their cancer go into remission in a small phase 2 clinical trial testing a treatment aimed at making chemotherapy more effective, according to Weill Cornell Medicine and NewYork-Presbyterian investigators.

The sixth annual Symposium on Entrepreneurship and Academic Drug Development, hosted Nov. 14, showcased Weill Cornell’s rich array of programs for supporting faculty who want to bring their discoveries to the health care marketplace.

Dr. Sheila Nirenberg, the Nanette Laitman Professor of Neurology and Neuroscience and a professor of physiology and biophysics at Weill Cornell Medicine, has received the Barbara McClintock Women Innovator Award at the Inaugural Women Innovator Awards.

The fifth annual symposium spotlighted an expanding list of entrepreneurial translation efforts at the institution.

Weill Cornell Medicine has received complementary grants from Genentech and the Leukemia & Lymphoma Society (LLS) to support a new program that aims to address socioeconomic and racial disparities and increase access to clinical trials for underserved patients with blood cancers living in Brooklyn and Queens.

The environment surrounding the cancerous cells of a lymphoma tumor has a strong influence on the progression of these blood-cell cancers and their responses to therapies.

Weill Cornell Medicine neuroscientist Dr. Li Gan is driving toward one of the most coveted medical breakthroughs: an effective treatment for Alzheimer’s disease.

Dr. John Leonard, an esteemed physician-scientist who specializes in lymphoma research and treatment, has been named senior associate dean for innovation and initiatives at Weill Cornell Medicine. 

Awards, honors, prizes and achievements for the month of May.

The addition of an oral immunomodulatory drug to a commonly employed antibody therapy is more effective against chronic, indolent lymphoma than the antibody alone, according to the results of a Phase 3 clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.

Weill Cornell Medicine has been awarded a five-year, $9 million Program Project Grant (P01) from the National Cancer Institute (NCI) to better understand how and why patients with an aggressive and incurable form of lymphoma initially respond to treatment, only to relapse over time.